Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASP7991
- Development stage
- Phase 3
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ASP7991 is a small molecule calcimimetic developed by Astellas Pharma for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. It acts as an agonist of the calcium-sensing receptor (CaSR) on parathyroid cell membranes to suppress parathyroid hormone (PTH) secretion. Clinical studies have evaluated its efficacy and safety in this patient population[4][5][7].
- Brand names
- Orkedia
- Other names
- 4-Carboxyphenyl (3S,4S)-3-[[[(1R)-1-(1-naphthalenyl)ethyl]amino]methyl]-4-phenyl-1-pyrrolidinecarboxylate1-Pyrrolidinecarboxylic acid, 3-[[[(1R)-1-(1-naphthalenyl)ethyl]amino]methyl]-4-phenyl-, 4-carboxyphenyl ester
02
Targets
CaSR (Extracellular calcium-sensing receptor)
Beyond the preview
Go deeper on ASP7991.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASP7991.